|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies investigated the role of HLA, specific myeloperoxidase (MPO) epitopes, CD4<sup>+</sup> T cells, and ANCA specificity in shaping the immune response in patients with anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis.
|
31383567 |
2020 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations suggest that the activation of granulocytes and local MPO release contribute to the pathogenesis of GN and vasculitis.
|
31476889 |
2020 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase-specific ANCA (MPO-ANCA) are implicated in the pathogenesis of vasculitis and GN.
|
31772138 |
2020 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
High serum hepcidin is associated with the occurrence of anemia in anti-myeloperoxidase antibody-associated vasculitis with normal kidney function: a cross-sectional study.
|
30923957 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with active MPO- or PR3-ANCA vasculitis or ANCA-negative pauci-immune glomerulonephritis were included.
|
30239910 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently the classical division of the ANCA vasculitides using clinical phenotype has come under scrutiny with evidence from epidemiological, genetic and outcome studies that perhaps these conditions should be classified on the basis of ANCA specificity into PR3-ANCA positive and MPO-ANCA positive groups.
|
29673090 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies.
|
31781107 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aortitis and pachymeningitis: an unusual combination in granulomatosis with polyangiitis (myeloperoxidase-associated vasculitis).
|
30696638 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently the classical division of the ANCA vasculitides using clinical phenotype has come under scrutiny with evidence from epidemiological, genetic and outcome studies that perhaps these conditions should be classified on the basis of ANCA specificity into PR3-ANCA positive and MPO-ANCA positive groups.
|
29707909 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ANCAs directed to proteinase 3 and myeloperoxidase (MPO) in particular are associated with distinct forms of small vessel vasculitides.
|
31719144 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study shows a partial efficacy of rituximab in renal function recovery and a low risk of infectious complications in patients with MPO vasculitis with severe renal involvement, in particular in the short term.
|
31088509 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
5.8% of IgA vasculitis patients had MPO-ANCA and poor outcomes of IgA vasculitis were not affected by the presence of ANCA.
|
31372719 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of 85 patients with ANCA and vasculitis included in this study, 67 (78.8%) had MPO-ANCA, 10 (11.8%) had PR3-ANCA, and 8 (9.4%) had both MPO- and PR3-ANCA.
|
31552433 |
2019 |
|
Vasculitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Microparticles expressing myeloperoxidase and complement C3a and C5a as markers of renal involvement in antineutrophil cytoplasmic antibody - associated vasculitis.
|
31371653 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among those positive for MPO antibodies, two of six (33%) in the discovery cohort and three of 12 (25%) in the replication cohort developed vasculitis.
|
31181198 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
No overlapping SNPs were found between PR3-ANCA and MPO-ANCA vasculitis.
|
30795559 |
2019 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pathological severity determines the renal recovery for anti-myeloperoxidase antibody-associated vasculitis requiring dialysis at disease onset: a retrospective study.
|
31362703 |
2019 |
|
Vasculitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated Level of Myeloperoxidase-Deoxyribonucleic Acid Complex in the Middle Ear Fluid Obtained From Patients With Otitis Media Associated With Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
|
29342044 |
2018 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, peroxidasin-specific antibodies were also found in serum from patients with anti-MPO vasculitis and were associated with significantly more active clinical disease.
|
30279272 |
2018 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clearly, though, the new testing strategy for ANCA in vasculitis must identify the ANCA target antigen, as PR3- and MPO-ANCA serotype correlate well with disease expression.
|
29395165 |
2018 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis.
|
30158055 |
2018 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The small vessel vasculitides granulomatosis with polyangiitis (GPA) and microscopic polyangiitis are associated with autoantibodies to neutrophil cytoplasm antigens (ANCA), principally proteinase-3 (PR3) and myeloperoxidase (MPO).
|
29447930 |
2018 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ANCA are usually of anti-MPO specificity and microscopic polyangiitis is the most frequent vasculitis.
|
30404113 |
2018 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies.
|
29790303 |
2018 |
|
Vasculitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, TNFα can induce leucocyte cell membrane expression of the autoantigens involved in vasculitis [proteinase 3 and myeloperoxidase (MPO)], thus priming cells for the effects of ANCA.
|
28391344 |
2017 |